NF-κB signaling pathway, inflammation and colorectal cancer

Chinese Journal of Cellular and Molecular Immunology

Volumn 6, Issue 5, 2009, Pages 327-334

  Soly, Wang ^a,b   Zhanjie, Liu ^a   Lunshan, Wang ^a   Xiaoren, Zhang ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b MEDICAL COLLEGE OF SOOCHOW UNIVERSITY   (China)

Author keywords

Colorectal cancer; Inflammation; NF B

Indexed keywords

ACETYLSALICYLIC ACID; ANTINEOPLASTIC AGENT; CELL PROTEIN; CHEMOKINE; CURCUMIN; CYCLIN D1; CYCLOOXYGENASE 2; CYTOKINE; GELATINASE B; GINSENG EXTRACT; GREEN TEA EXTRACT; I KAPPA B; I KAPPA B KINASE BETA INHIBITOR; I KAPPA B KINASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 8; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PROTEASOME INHIBITOR; RESVERATROL; SALAZOSULFAPYRIDINE; UNCLASSIFIED DRUG; VASCULOTROPIN; APOPTOSIS REGULATORY PROTEIN; PROTEIN SUBUNIT; RECOMBINANT CYTOKINE;

ANGIOGENESIS; ANTIINFLAMMATORY ACTIVITY; CANCER CELL; CANCER GROWTH; CANCER INVASION; CANCER RISK; CANCER STAGING; CELL PROLIFERATION; CELL TRANSFORMATION; COLON CARCINOGENESIS; COLORECTAL CANCER; DISEASE ACTIVITY; DRUG EFFICACY; ENTERITIS; GENE EXPRESSION; HUMAN; INHIBITION KINETICS; METASTASIS; NONHUMAN; PROTEIN FAMILY; REVIEW; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; CHEMISTRY; COLORECTAL TUMOR; GENE EXPRESSION REGULATION; GENETICS; INFLAMMATION; METABOLISM; PATHOLOGY; APOPTOSIS; ARTICLE; CANCER CELL DESTRUCTION; CANCER CHEMOTHERAPY; CANCER PREVENTION; CARCINOGENESIS; CHRONIC INFLAMMATION; CROHN DISEASE; GENE TARGETING; GENETIC ASSOCIATION; IMMUNOMODULATION; PROTEIN FUNCTION; PROTEIN TARGETING; RISK REDUCTION; STOMACH CANCER; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION; TUMOR PROMOTION; ULCERATIVE COLITIS;

ANIMALS; APOPTOSIS REGULATORY PROTEINS; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; COLORECTAL NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INFLAMMATION; INFLAMMATORY BOWEL DISEASES; NEOPLASM METASTASIS; NF-KAPPA B; PROTEIN SUBUNITS; SIGNAL TRANSDUCTION;

EID: 70350764831     PISSN: 10078738     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (99)

1. Flossmann E, Rothwell PM. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet. 2007;369:1603-1613. (Pubitemid 46710123)
2. Chan AT, Ogino S, Fuchs CS. Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med. 2007;356:2131-2142. (Pubitemid 47010839)
3. Mantovani A. Cancer: inflammation by remote control. Nature. 2005;435:752-753.
4. Baniyash M. Chronic inflammation, immunosuppression and cancer: new insights and outlook. Semin Cancer Biol. 2006; 16:80-88. (Pubitemid 43139712)
5. Hagemann T, Balkwill F, Lawrence T. Inflammation and cancer: a double-edged sword. Cancer Cell. 2007;12:300-301.
6. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454:436-444.
7. Greten FR, Eckmann L, Greten TF, et al. IKKβ links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell. 2004;118:285-296. (Pubitemid 39061110)
8. Pikarsky E, Porat RM, Stein I, et al. NF-κB functions as a tumour promoter in inflammation-associated cancer. Nature. 2004;431:461-466. (Pubitemid 39329586)
9. Karin M. Nuclear factor-κB in cancer development and progression. Nature. 2006;441:431-436. (Pubitemid 44050137)
10. Luo JL, Kamata H, Karin M. IKK/NF-κB signaling: balancing life and death - a new approach to cancer therapy. J Clin Invest. 2005;115:2625-2632.
11. Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-κB activity. Annu Rev Immunol. 2000;18:621-663.
12. Hayden MS, Ghosh S. Signaling to NF-κB. Genes Dev. 2004;18:2195-2224.
13. Weir HK, Thun MJ, Hankey BF, et al. Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control. J Natl Cancer Inst. 2003;95:1276-1299.
14. Baud V, Karin M. Is NF-κB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov. 2009;8:33-40.
15. Lee CH, Jeon YT, Kim SH, Song YS. NF-κB as a potential molecular target for cancer therapy. Biofactors. 2007;29:19-35. (Pubitemid 46985299)
16. Ghosh S, Hayden MS. New regulators of NF-κB in inflammation. Nat Rev Immunol. 2008;8:837-848.
17. Baldwin AS, Jr. The NF-κB and IκB proteins: new discoveries and insights. Annu Rev Immunol. 1996;14:649-683.
18. Ghosh S, Karin M. Missing pieces in the NF-κB puzzle. Cell. 2002;109 Suppl:S81-96.
19. Ghosh S, May MJ, Kopp EB. NF-κB and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol. 1998;16:225-260. (Pubitemid 28183365)
20. Senftleben U, Li ZW, Baud V, Karin M. IKKβ is essential for protecting T cells from TNFα-induced apoptosis. Immunity. 2001;14:217-230. (Pubitemid 32289287)
21. Karin M, Lin A. NF-κB at the crossroads of life and death. Nat Immunol. 2002;3:221-227.
22. Xiao G, Harhaj EW, Sun SC. NF-κB-inducing kinase regulates the processing of NF-κB2 p100. Mol Cell. 2001;7:401-409. (Pubitemid 32206507)
23. Desai A, Konda VR, Darland G, et al. META060 inhibits multiple kinases in the NF-κB pathway and suppresses LPS - mediated inflammation in vitro and ex vivo. Inflamm Res. 2009;58:229-234.
24. Pindolia KR, Noth CJ, Xu YX, Janakiraman N, Chapman RA, Gautam SC. IL-4 upregulates IL-1-induced chemokine gene expression in bone marrow stromal cells by enhancing NF-kB activation. Hematopathol Mol Hematol. 1996;10:171-185. (Pubitemid 27101950)
25. Senftleben U, Cao Y, Xiao G, et al. Activation by IKKα of a second, evolutionary conserved, NF-κB signaling pathway. Science. 2001;293:1495-1499. (Pubitemid 32801552)
26. Hayden MS, Ghosh S. Shared principles in NF-κB signaling. Cell. 2008;132:344-362.
27. Li ZW, Chu W, Hu Y, et al. The IKKβ subunit of IκB kinase (IKK) is essential for nuclear factor κB activation and prevention of apoptosis. J Exp Med. 1999;189:1839-1845. (Pubitemid 29272700)
28. Baud V, Karin M. Signal transduction by tumor necrosis factor and its relatives. Trends Cell Biol. 2001;11:372-377. (Pubitemid 32900529)
29. Bonizzi G, Karin M. The two NF-κB activation pathways and their role in innate and adaptive immunity. Trends Immunol. 2004;25:280-288.
30. Derudder E, Dejardin E, Pritchard LL, Green DR, Korner M, Baud V. RelB/p50 dimers are differentially regulated by tumor necrosis factor-α and lymphotoxin-β receptor activation: critical roles for p100. J Biol Chem. 2003;278:23278-23284. (Pubitemid 36830141)
31. Coope HJ, Atkinson PG, Huhse B, et al. CD40 regulates the processing of NF-κB2 p100 to p52. EMBO J. 2002;21:5375-5385. (Pubitemid 35231017)
32. Dejardin E. The alternative NF-κB pathway from biochemistry to biology: pitfalls and promises for future drug development. Biochem Pharmacol. 2006;72:1161-1179. (Pubitemid 44479741)
33. Senftleben U, Karin M. The IKK/NF-κB pathway. Crit Care Med. 2002;30:S18-S26.
34. Keats JJ, Fonseca R, Chesi M, et al. Promiscuous mutations activate the noncanonical NF-κB pathway in multiple myeloma. Cancer Cell. 2007;12:131-144. (Pubitemid 47208626)
35. Annunziata CM, Davis RE, Demchenko Y, et al. Frequent engagement of the classical and alternative NF-κB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell. 2007;12:115-130. (Pubitemid 47199123)
36. Kato T, Jr, Delhase M, Hoffmann A, Karin M. CK2 is a C-terminal IκB kinase responsible for NF-κB activation during the UV response. Mol Cell. 2003;12:829-839. (Pubitemid 37352777)
37. Algul H, Tando Y, Beil M, et al. Different modes of NF-κB/Rel activation in pancreatic lobules. Am J Physiol Gastrointest Liver Physiol. 2002;283:G270-281.
38. Byun MS, Jeon KI, Choi JW, Shim JY, Jue DM. Dual effect of oxidative stress on NF-κB activation in HeLa cells. Exp Mol Med. 2002;34:332-339.
39. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357:539-545.
40. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860-867.
41. Lawrence T, Willoughby DA, Gilroy DW. Anti-inflammatory lipid mediators and insights into the resolution of inflammation. Nat Rev Immunol. 2002;2:787-795.
42. Vakkila J, Lotze MT. Inflammation and necrosis promote tumour growth. Nat Rev Immunol. 2004;4:641-648. (Pubitemid 39025049)
43. Grivennikov S, Karin E, Terzic J, et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell. 2009;15:103-113.
44. Schottenfeld D, Beebe-Dimmer J. Chronic inflammation: a common and important factor in the pathogenesis of neoplasia. CA Cancer J Clin. 2006;56:69-83.
45. Schottenfeld D, Beebe-Dimmer JL. Advances in cancer epidemiology: understanding causal mechanisms and the evidence for implementing interventions. Annu Rev Public Health. 2005;26:37-60. (Pubitemid 40547375)
46. Pisani P, Parkin DM, Munoz N, Ferlay J. Cancer and infection: estimates of the attributable fraction in 1990. Cancer Epidemiol Biomarkers Prev. 1997;6:387-400.
47. Hiscott J, Kwon H, Genin P. Hostile takeovers: viral appropriation of the NF-κB pathway. J Clin Invest. 2001;107:143-151. (Pubitemid 32096827)
48. Chan CF, Yau TO, Jin DY, Wong CM, Fan ST, Ng IO. Evaluation of nuclear factor-κB, urokinase-type plasminogen activator, and HBx and their clinicopathological significance in hepatocellular carcinoma. Clin Cancer Res. 2004;10:4140-4149.
49. Herrero R, Castellsague X, Pawlita M, et al. Human papillomavirus and oral cancer: the international agency for research on cancer multicenter study. J Natl Cancer Inst. 2003;95:1772-1783.
50. IAfRoC (IARC). Monographs on the evaluation of carcinogenic risk to humans: human papillomaviruses. Lyon, France: IARC Publications; 2005.
51. Aggarwal BB, Shishodia S, Sandur SK, Pandey MK, Sethi G. Inflammation and cancer: how hot is the link? Biochem Pharmacol. 2006;72:1605-1621.
52. Tsurutani J, Castillo SS, Brognard J, et al. Tobacco components stimulate Akt-dependent proliferation and NFκB-dependent survival in lung cancer cells. Carcinogenesis. 2005;26:1182-1195. (Pubitemid 41417895)
53. Wu AH, Pearce CL, Tseng CC, Templeman C, Pike MC. Markers of inflammation and risk of ovarian cancer in Los Angeles County. Int J Cancer. 2009;124:1409-1415.
54. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 2001;48:526-535. (Pubitemid 32234798)
55. Seril DN, Liao J, Yang GY, Yang CS. Oxidative stress and ulcerative colitis-associated carcinogenesis: studies in humans and animal models. Carcinogenesis. 2003;24:353-362. (Pubitemid 36432628)
56. Meira LB, Bugni JM, Green SL, et al. DNA damage induced by chronic inflammation contributes to colon carcinogenesis in mice. J Clin Invest. 2008;118:2516-2525.
57. Sangha S, Yao M, Wolfe MM. Non-steroidal anti-inflammatory drugs and colorectal cancer prevention. Postgrad Med J. 2005;81:223-227.
58. Hoffmeister M, Chang-Claude J, Brenner H. Do older adults using NSAIDs have a reduced risk of colorectal cancer? Drugs Aging. 2006;23:513-523.
59. Bertagnolli MM, Eagle CJ, Zauber AG, et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med. 2006;355:873-884. (Pubitemid 44315980)
60. Steinbach G, Lynch PM, Phillips RK, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med. 2000;342:1946-1952. (Pubitemid 30419089)
61. Karin M, Lawrence T, Nizet V. Innate immunity gone awry: linking microbial infections to chronic inflammation and cancer. Cell. 2006;124:823-835. (Pubitemid 43261455)
62. Lin WW, Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest. 2007;117: 1175-1183. (Pubitemid 46718402)
63. Karin M, Cao Y, Greten FR, Li ZW. NF-κB in cancer: from innocent bystander to major culprit. Nat Rev Cancer. 2002;2:301-310. (Pubitemid 37328783)
64. Richmond A. NF-κB, chemokine gene transcription and tumour growth. Nat Rev Immunol. 2002;2:664-674. (Pubitemid 37328724)
65. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57-70.
66. Schulze-Bergkamen H, Krammer PH. Apoptosis in cancer-implications for therapy. Semin Oncol. 2004;31:90-119.
67. Kucharczak J, Simmons MJ, Fan Y, Gelinas C. To be, or not to be: NF-κB is the answer-role of Rel/NF-κB in the regulation of apoptosis. Oncogene. 2003;22:8961-8982.
68. Neurath MF, Pettersson S, Meyer zum Buschenfelde KH, Strober W. Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-κB abrogates established experimental colitis in mice. Nat Med. 1996;2:998-1004.
69. Rogler G, Brand K, Vogl D, et al. Nuclear factor κB is activated in macrophages and epithelial cells of inflamed intestinal mucosa. Gastroenterology. 1998;115:357-369. (Pubitemid 28363428)
70. Ardite E, Panes J, Miranda M, et al. Effects of steroid treatment on activation of nuclear factor κB in patients with inflammatory bowel disease. Br J Pharmacol. 1998;124:431-433. (Pubitemid 28254496)
71. Becker C, Fantini MC, Schramm C, et al. TGF-β suppresses tumor progression in colon cancer by inhibition of IL-6 transsignaling. Immunity. 2004;21:491-501. (Pubitemid 39370505)
72. Greten FR, Arkan MC, Bollrath J, et al. NF-κB is a negative regulator of IL-1β secretion as revealed by genetic and pharmacological inhibition of IKKβ. Cell. 2007;130:918-931. (Pubitemid 47332565)
73. Guttridge DC, Albanese C, Reuther JY, Pestell RG, Baldwin AS, Jr. NF-κB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol Cell Biol. 1999;19:5785-5799.
74. Chen C, Edelstein LC, Gelinas C. The Rel/NF-κB family directly activates expression of the apoptosis inhibitor Bcl-x(L). Mol Cell Biol. 2000;20:2687-2695.
75. Fernandez-Majada V, Aguilera C, Villanueva A, et al. Nuclear IKK activity leads to dysregulated notch-dependent gene expression in colorectal cancer. Proc Natl Acad Sci U S A. 2007;104:276-281. (Pubitemid 46068022)
76. Tew GW, Lorimer EL, Berg TJ, Zhi H, Li R, Williams CL. SmgGDS regulates cell proliferation, migration, and NF-κB transcriptional activity in non-small cell lung carcinoma. J Biol Chem. 2008;283:963-976.
77. Rahman KM, Ali S, Aboukameel A, Sarkar SH, et al. Inactivation of NF-κB by 3,3′-diindolylmethane contributes to increased apoptosis induced by chemotherapeutic agent in breast cancer cells. Mol Cancer Ther. 2007;6:2757-2765.
78. Luo JL, Maeda S, Hsu LC, Yagita H, Karin M. Inhibition of NF-κB in cancer cells converts inflammation-induced tumor growth mediated by TNFα to TRAIL-mediated tumor regression. Cancer Cell. 2004;6:297-305. (Pubitemid 39222042)
79. Baldwin AS. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-κB. J Clin Invest. 2001;107:241-246. (Pubitemid 32157954)
80. Loch T, Michalski B, Mazurek U, Graniczka M. (Vascular endothelial growth factor (VEGF) and its role in neoplastic processes). Postepy Hig Med Dosw. 2001;55:257-274.
81. Huang S, DeGuzman A, Bucana CD, Fidler IJ. Nuclear factor-κB activity correlates with growth, angiogenesis, and metastasis of human melanoma cells in nude mice. Clin Cancer Res. 2000;6:2573-2581. (Pubitemid 30399230)
82. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell. 1998;93:705-716. (Pubitemid 28257578)
83. Choo MK, Sakurai H, Kim DH, Saiki I. A ginseng saponin metabolite suppresses tumor necrosis factor-α-promoted metastasis by suppressing nuclear factor-κB signaling in murine colon cancer cells. Oncol Rep. 2008;19:595-600.
84. Hayden MS, West AP, Ghosh S. NF-κB and the immune response. Oncogene. 2006;25:6758-6780.
85. Monks NR, Biswas DK, Pardee AB. Blocking anti-apoptosis as a strategy for cancer chemotherapy: NF-κB as a target. J Cell Biochem. 2004;92:646-650.
86. Ravi R, Bedi A. NF-κB in cancer - a friend turned foe. Drug Resist Updat. 2004;7:53-67.
87. Bharti AC, Aggarwal BB. Chemopreventive agents induce suppression of nuclear factor-κB leading to chemosensitization. Ann N Y Acad Sci. 2002;973:392-395.
88. Frelin C, Imbert V, Griessinger E, Loubat A, Dreano M, Peyron JF. AS602868, a pharmacological inhibitor of IKK2, reveals the apoptotic potential of TNF-α in Jurkat leukemic cells. Oncogene. 2003;22:8187-8194. (Pubitemid 37487309)
89. Frelin C, Imbert V, Griessinger E, et al. Targeting NF-κB activation via pharmacologic inhibition of IKK2-induced apoptosis of human acute myeloid leukemia cells. Blood. 2005;105:804-811.
90. Ziegelbauer K, Gantner F, Lukacs NW, et al. A selective novel low-molecular-weight inhibitor of IκB kinase-β (IKK-β) prevents pulmonary inflammation and shows broad antiinflammatory activity. Br J Pharmacol. 2005;145:178-192. (Pubitemid 40756522)
91. Weber CK, Liptay S, Wirth T, Adler G, Schmid RM. Suppression of NF-βB activity by sulfasalazine is mediated by direct inhibition of IκB kinases α and β. Gastroenterology. 2000;119:1209-1218.
92. Majumdar S, Aggarwal BB. Methotrexate suppresses NF-κB activation through inhibition of IκBα phosphorylation and degradation. J Immunol. 2001;167:2911-2920.
93. Farrow DC, Vaughan TL, Hansten PD, et al. Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev. 1998;7:97-102.
94. Zaridze D, Borisova E, Maximovitch D, Chkhikvadze V. Aspirin protects against gastric cancer: results of a case-control study from Moscow, Russia. Int J Cancer. 1999;82:473-476. (Pubitemid 29343443)
95. Naugler WE, Karin M. NF-κB and cancer-identifying targets and mechanisms. Curr Opin Genet Dev. 2008;18:19-26.
96. Katsman A, Umezawa K, Bonavida B. Chemosensitization and immunosensitization of resistant cancer cells to apoptosis and inhibition of metastasis by the specific NF-κB inhibitor DHMEQ. Curr Pharm Des. 2009;15:792-808.
97. Salminen A, Lehtonen M, Suuronen T, Kaarniranta K, Huuskonen J. Terpenoids: natural inhibitors of NF-κB signaling with anti-inflammatory and anticancer potential. Cell Mol Life Sci. 2008;65:2979-2999.
98. Karin M, Yamamoto Y, Wang QM. The IKK NF-κB system: a treasure trove for drug development. Nat Rev Drug Discov. 2004;3:17-26. (Pubitemid 38088695)
99. Yu M, Yeh J, Van Waes C. Protein kinase casein kinase 2 mediates inhibitor-κB kinase and aberrant nuclear factor-κB activation by serum factor(s) in head and neck squamous carcinoma cells. Cancer Res. 2006;66:6722-6731. (Pubitemid 44085630)